AskBio

AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)

AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United States Therapy granted United States Food and Drug Administration (FDA) Fast Track and Orphan Drug designations Pompe disease is a rare genetic metabolic disorder that without early detection and treatment can lead to premature death. 8 January 2026 -- North Carolina, US...
20 T.W. Alexander Drive Suite, 110 Research Triangle Park, NC 27709